New Reference: Trastuzumab Deruxtecan in her2-Positive Advanced Gastroesophageal Cancer
Study
Single-arm, multicenter, phase II trial HER2 positive, unresectable or metastatic gastric or gastro-oesophageal junction cancer, progressive disease on or after first-line therapy with a trastuzumab-containing regimen Trastuzumab-deruxtecan (n=79
Efficacy
cORR: 42% [33 of 79 pts] CR: 5% [ 4 of 79 pts] mPFS: 5.6 mos [4.2-8.3] mOS: 12.1 mos [9.4-15.4] mDoR: 8.1 mos [5.9-NR]
Safety
Grade3: Anemia (14%), nausea (8%), neutropenia (8%)
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study
Reviewed by Elvin Chalabiyev, MD on Aug 20, 2023